PathoVax is a biotechnology company focused on the development of a universal human papillomavirus (HPV) vaccine to provide prophylaxis against HPV-related cancers and diseases. It applies engineering approaches that leverage the natural virology of papillomaviruses, creating platform delivery medicines. PathoVax's pilot vaccine, RGVax, provides protection against oncogenic HPVs and others that cause various warts.